Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

ROCHE FARMACEUTICA QUIMICA LDA

NIF 500233810
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €22,898,653 116 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €22,898,653 116 contracts
A2 · Late Publication €23,078,598,063 6,331 contracts
Contract published to BASE more than 10 days after the signing date
LOW €23,078,598,063 6,331 contracts
A5 · Threshold Splitting €26,112,774 266 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €26,112,774 266 contracts
A6 · Low Competition €130,757,094 93 contracts
Only one bidder participated in a competitive procedure
MEDIUM €130,757,094 93 contracts
A9 · Price Overrun €55,233 1 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €55,233 1 contracts
A9 · Abnormal Price Reduction €26,319,014,877 1,873 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €26,319,014,877 1,873 contracts
C3 · Missing Mandatory Fields €35,643,635 96 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €35,643,635 96 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

899
€3,868,347,887
159
€1,587,118,832
259
€879,737,792
150
€866,312,888
618
€846,372,143
306
€841,593,275
70
€834,639,457
1,000
€791,977,813
24
€770,392,816
103
€765,674,331
38
€747,275,352
81
€742,372,527
367
€698,589,811
524
€669,957,258
73
€661,866,242
45
€651,950,632
50
€623,265,140
37
€605,733,844
338
€604,344,776
444
€600,743,498
Page 1 of 4 · 69 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 6 · 266 contracts

261X000032 - MOSUNETUZUMAB varias dosagens.
PT · 13447133 · Contratação excluída II
A5 · Threshold Splitting
€74,238 2026-02-16
CPA 2023/492 - Medicamentos anti-infeciosos
PT · 13075647 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€19,760 2025-12-30
OLAPARIB 100 MG COMP E TRASTUZUMAB EMTANSINA 100 MG PÓ CONC SOL INJ FR IV
PT · 12198519 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€74,830 2025-12-23
AQUISIÇÃO DE VARIOS MEDICAMENTOS SPMS PARA 2025 -24 - ULSLO
PT · 12702318 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€19,746 2025-12-10
251Y000394/13559 - VÁRIOS MEDICAMENTOS
PT · 11956146 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€148,226 2025-11-19
Medicamentos
PT · 12127154 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,119 2025-11-06
Medicamentos
PT · 12065740 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,119 2025-11-06
Q1/2318/2025 - AGREGAÇÃO URGENTE - MEDICAMENTOS DO FORO ONCOLÓGICO E IMUNOMODULADORES
PT · 11976878 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€5,294,078 2025-10-22
61/130/2026 - Medicamentos Tocilizumab
PT · 12989817 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€72,724 2025-10-16
Medicamentos
PT · 63156907755749f67ac9 · Ajuste Direto Regime G...
A2 · Late Publication A5 · Threshold Splitting
€4,823 2025-10-13
Aquisição de Cisplatina 1 mg/ml sol inj fr 100 ml IV, Cisplatina 1 mg/ml sol inj fr 50 ml IV, Icatibant 30 mg/3 ml sol inj ser 3 ml SC, Oxaliplatina 5 mg/ml sol inj fr 40 ml IV e Pertuzumab 60 mg/ml + Trastuzumab 60 mg/ml sol inj fr 10 ml SC
PT · 11666395 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€73,063 2025-08-21
ADCM3487/25 - MEDICAMENTOS DIVERSOS
PT · fe8ebe44b311982a7c8a · Ajuste Direto Regime G...
A2 · Late Publication A5 · Threshold Splitting
€4,936 2025-08-11
ADCM 3380/25 - MEDICAMENTOS DIVERSOS
PT · 11634360 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,479 2025-08-01
Aquisição de Tocilizumab 162 mg SC Roche - Doente Especif – Nova qtd
PT · 11607863 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€4,823 2025-07-25
ADCM3064/25 - MEDICAMENTOS DIVERSOS
PT · 11616342 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€149,723 2025-07-11
Aquisição de Tocilizumab
PT · 11664745 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€146,200 2025-07-02
61/3840/2025 Medicamento Tocilizumab
PT · 11560219 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€4,859 2025-07-01
050102702025 AQUISIÇÃO DE MEDICAMENTOS PARA AS NECESSIDADES IMEDIATAS DOS DOENTES-DESPACHO 1571-B/2016
PT · 11586709 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€72,886 2025-06-27
Medicamentos
PT · 11533295 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,310 2025-06-12
251Y000025/13559 - TOCILIZUMAB (VÁRIAS DOSAGENS)
PT · 11490750 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€19,436 2025-06-09
ADCM 2027/25 - medicamentos diversos
PT · 11520566 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,649 2025-05-05
Medicamentos
PT · 11382197 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€72,968 2025-04-17
Epoetina beta 30 000 U.I./0.6 ml Sol inj Ser 0.6 ml IV SC
PT · 11513205 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,800 2025-03-25
Epoetina beta 30 000 U.I./0.6 ml Sol inj Ser 0.6 ml IV SC
PT · 11368688 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,800 2025-03-03
Epoetina beta 30 000 U.I./0.6 ml Sol inj Ser 0.6 ml IV SC
PT · 11318114 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,800 2025-01-21
2024010839 – Aquisição de medicamentos
PT · 11102507 · Ajuste Direto Regime G...
A5 · Threshold Splitting A6 · Low Competition
€19,207 2024-12-20
Convite à apresentação de propostas ao abrigo do(s) acordo(s)-quadro 2021/061 - Medicamentos diversos, 2023/304 - Medicamentos do grupo 4: sangue, 2023/305 - Medicamentos do aparelho cardiovascular, 2023/436 - Medicamentos para o sistema nervoso central, 2023/437 - Medicação antialérgica, vitaminas e sais minerais e medicamentos usados no tratamento de intoxicações, 2023/491 - Medicamentos do foro oncológico e imunomoduladores, 2023/671 - Medicamentos diversos e 2024/899 - Medicamentos do aparelho respiratório para aquisição de medicamentos
PT · 11224369 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€144,855 2024-12-19
Aquisição de EMICIZUMAB [150 MG/ 0,4 ML; SOL INJ; FRS] ao abrigo do acordo quadro 2023/304
PT · 12977043 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€74,011 2024-12-05
050104152024 - CPA 2023/304
PT · 11412505 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€148,023 2024-12-04
OCRELIZUMAB 300 MG (CONCENTRADO PARA PERFUSÃO) INJ (PC.04017.2024)
PT · 11138801 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€74,998 2024-12-02
AQUISIÇÃO DE EPOETINA BETA INJ
PT · 11009063 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,537 2024-10-30
MEDICAMENTOS
PT · 10979995 · Ajuste Direto Regime G...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€71,694 2024-10-09
VÁRIOS MEDICAMENTOS
PT · 10965395 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,840 2024-10-02
Aquisição de FARICIMAB IVI 120MG/ML 0,24ML SOL INJ, ao Lab. Roche, para a ULSASI, para o ano 2024
PT · 10917649 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€145,380 2024-09-12
050103312024 AQUISIÇÃO DE MEDICAMENTOS PARA AS NECESSIDADES IMEDIATAS DOS DOENTES-DESPACHO 1571-B/2016
PT · 10978758 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€74,011 2024-09-09
Tocilizumab 20 mg/ml sol inj fr 10 ml IV e Tocilizumab 20 mg/ml sol inj fr 20 ml IV
PT · 10927634 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,180 2024-09-06
Aquisição de Ocrelizumab 300 mg/10 ml Sol inj Fr 10 ml IV à Roche Farmacêutica Química, Lda.
PT · 10991441 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,999 2024-09-04
MEDICAMENTOS
PT · 10914606 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,659 2024-09-04
040127412024 - MOSUNETUZUMAB SOL INJ FR
PT · 10946249 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€148,596 2024-08-29
TRASTUZUMAB 600MG/5ML SOL INJ AMP S.C. (PC.02722.2024)
PT · 10898295 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€149,295 2024-08-21
VISMODEGIB 150MG CAPS (PC.02443.2024)
PT · 10869137 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€19,762 2024-07-22
Polatuzumab vedotina 140 mg Pó conc sol inj Fr IV
PT · 10858117 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,410 2024-07-15
Polatuzumab vedotina 140 mg Pó conc sol inj Fr IV
PT · b73babad13d2fbd95751 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,410 2024-07-15
BEAD20240365 - AQUISIÇÃO DE IMUNOMODULADORES - OCRELIZUMAB - 3 MESES
PT · 10815979 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A6 · Low Competition
€149,996 2024-07-11
Epoetina beta 30000 U.I./0.6 ml Sol inj Ser 0.6 ml IV SC
PT · 10810385 · Ajuste Direto Regime G...
A2 · Late Publication A5 · Threshold Splitting
€4,800 2024-06-20
EPOETINA BETA 30000 U.I./0.6 ML SOL INJ SER 0.6 ML IV SC
PT · 10989947 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€73,632 2024-06-11
AQUISIÇÃO DE AQUISIÇÃO DE MEDICAMENTOS VÁRIOS CPA 2023/491
PT · 10757219 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€144,273 2024-06-06
Aquisição de Tocilizumab - 2024 - ULSLO.
PT · 10755469 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€4,944 2024-06-05
Aquisição do medicamento "Tocilizumab sol inj"
PT · 10725421 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€143,433 2024-05-14
IMUNOMODULADORES - TRASTUZUMAB EMTANSINA - 1.º SEMESTRE
PT · 10711232 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A6 · Low Competition
€73,989 2024-05-10
Next →
Overview
Total Value Won
€26,981,433,453
Contracts Won
8,787
Score 290915 · CRITICAL RISK
NIF
500233810
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

No director data imported yet.

Director and fiscal identity data for Portuguese companies can be found in the Registo Comercial (publicacoes.mj.pt).

Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned